Eli Lilly and Company is committed to principles of medical research that define the ethical conduct, funding and communication of clinical research. The principles of medical research include a clinical trial registry policy that defines standards for disclosure of Lilly clinical trial data and commits to an independent third party audit and verification of adherence to the defined standards of disclosure.
In December 2004, Eli Lilly and Company launched its clinical trial registry (www.lillytrials.com) to demonstrate the company's commitment to data transparency by publicly disclosing information on clinical trials at the time of trial initiation and a summary of their results at the time of trial completion. To provide independent confirmation of adherence to its commitments, Eli Lilly and Company retained a compliance consulting firm, SEC Associates, Inc. , to review the clinical trial registry process, audit the associated clinical trial information and to publicly disclose their findings.
The scope of the audit included the following criteria as defined in Eli Lilly and Company's policy of public data disclosure: